Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. develops precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. Its news centers on investigational programs including zidesamtinib for ROS1-positive NSCLC, neladalkib for ALK-positive NSCLC, and HER2-altered NSCLC research, with updates on clinical data from ARROS-1 and ALKOVE-1, FDA submission activity, companion-diagnostic collaborations, and discovery-stage programs.
Company updates also cover quarterly financial results, research and development spending, cash resources, commercial-readiness activities for potential oncology launches, medical-meeting presentations, and leadership or governance developments tied to its clinical-stage biopharmaceutical model.
Nuvalent (Nasdaq: NUVL) will present patient-reported outcomes from the Phase 2 portion of the ARROS-1 trial of zidesamtinib, a ROS1-selective investigational inhibitor, plus encore pivotal efficacy and safety data from ARROS-1.
Two poster presentations are scheduled at the 2025 IASLC ASCO North America Conference on Lung Cancer in Chicago (Dec 5-7, 2025): Abstract PP01.41 (PROs and health-related quality of life) and Abstract PP01.32 (pivotal efficacy and safety). Both posters are on Saturday, December 6, 2025, 4:00-5:30 p.m. ET, presented by Melissa Laurie, Pharm.D., M.S., M.B.A., and Stephen V. Liu, M.D.
Nuvalent (Nasdaq: NUVL) reported third quarter 2025 results and pipeline progress, including completion of a rolling NDA submission for zidesamtinib in TKI pre-treated ROS1-positive NSCLC and an on‑track timeline to report topline pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC by year-end 2025.
The company highlighted preliminary neladalkib activity in ALK-positive solid tumors, new preclinical NVL-330 data showing brain penetration and intracranial regressions, ongoing Phase 3 ALKAZAR and Phase 1 HEROEX-1 trials, and a cash position of $943.1M supporting runway into 2028. Q3 expenses: R&D $83.8M, G&A $28.9M; net loss $122.4M.
Nuvalent (NASDAQ: NUVL) reported preliminary ALKOVE-1 data for neladalkib in advanced ALK-positive solid tumors beyond NSCLC with a data cutoff of August 7, 2025. Among 34 response-evaluable patients across 14 tumor types, overall objective response rate was 44% (15/34), including 9/13 ALK TKI‑naïve and 6/21 TKI‑pretreated patients. Most patients (32/34) received the recommended Phase 2 dose of 150 mg once daily.
Responses included durable case-study responses ongoing ~10–16 months and one confirmed intracranial complete response. Safety was described as generally well-tolerated with 8.8% dose reductions and no treatment-related discontinuations as of cutoff. Global Phase 2 enrollment continues; topline pivotal NSCLC data expected by end of 2025.
Nuvalent (Nasdaq: NUVL) will present new preclinical data for its HER2-selective inhibitor NVL-330 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025 in Boston.
The poster, titled “Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor” (Abstract No. B057), is authored by Yuting Sun and colleagues and will be presented during Poster Session B on Friday, October 24, 2025, 12:30–4:00 p.m. ET in Exhibit Hall D. Yuting Sun is listed as presenter and corresponding author.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming UBS 2025 Virtual Oncology Day. The company's CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat on October 1, 2025, at 3:30 p.m. ET.
Investors can access the live webcast through Nuvalent's website investor section, where it will remain available for 30 days after the presentation.
Nuvalent (Nasdaq: NUVL) presented pivotal data for zidesamtinib, its novel ROS1-selective inhibitor, for treating TKI pre-treated patients with advanced ROS1-positive NSCLC at WCLC 2025. The data, initially announced in June 2025, supports the company's ongoing rolling NDA submission to the FDA.
The FDA has accepted the NDA for the Real-Time Oncology Review (RTOR) program, enabling earlier submission of efficacy and safety results. Nuvalent expects to complete the rolling NDA submission in Q3 2025 and is exploring potential line-agnostic expansion opportunities with the FDA.
The drug aims to address unmet needs in ROS1-positive NSCLC patients, particularly those intolerant to current TKIs or experiencing disease progression with brain metastases or resistance mutations.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.
Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.
Nuvalent (Nasdaq: NUVL) announced that pivotal data from their ARROS-1 Phase 1/2 clinical trial for zidesamtinib, their novel ROS1-selective inhibitor, will be presented at the WCLC 2025 Presidential Symposium in Barcelona. The presentation will showcase results for both TKI pre-treated and TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer (NSCLC).
The company has initiated a rolling NDA submission for zidesamtinib in TKI pre-treated patients, with FDA accepting it under the Real-Time Oncology Review (RTOR) pilot program. Nuvalent targets completion of the NDA submission in Q3 2025 and is exploring potential line-agnostic expansion opportunities with the FDA.
Nuvalent (Nasdaq: NUVL) reported significant pipeline progress and Q2 2025 financial results. The company initiated a rolling NDA submission for zidesamtinib for ROS1-positive NSCLC treatment, targeting completion in Q3 2025. They also launched the ALKAZAR Phase 3 trial of neladalkib for front-line ALK-positive NSCLC.
Key developments include the promotion of Jason Waters to SVP, Commercial and appointment of Christy Oliger to the board. The company maintains a strong financial position with $1.0 billion in cash as of June 30, 2025, expected to fund operations into 2028. Q2 2025 financial results showed R&D expenses of $80.9M, G&A expenses of $23.7M, and a net loss of $99.7M.
Upcoming milestones include topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025 and preliminary data presentation at ESMO Congress 2025 for ALK-positive solid tumors beyond NSCLC.
Nuvalent (NASDAQ: NUVL) has initiated ALKAZAR, a global Phase 3 randomized controlled trial evaluating neladalkib for treatment-naive patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The study will compare neladalkib against ALECENSA® (alectinib), a current front-line standard treatment.
The trial will enroll approximately 450 TKI-naïve patients, randomized 1:1 to receive either neladalkib or alectinib monotherapy. The primary endpoint is progression-free survival (PFS), with multiple secondary endpoints including overall survival and intracranial response measures.
Neladalkib is also being evaluated in the ALKOVE-1 Phase 1/2 trial, where Phase 1 data showed durable clinical responses in heavily pre-treated patients, including those with brain metastases and resistance mutations. Topline pivotal data from ALKOVE-1's Phase 2 portion is expected by year-end 2025.